Stock Events

Stock Events

Search...

Nevro

$5.82

12

-$0.03-0.51% Wednesday 20:00

Statistics

Day High

6.28

Day Low

5.8

52W High

22.64

52W Low

4.38

Volume

430,236

Avg. Volume

695,088

Mkt Cap

230.78M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

30OctExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.05

-0.79

-0.52

-0.25

Expected EPS

-0.82336

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVRO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Medtronic is a leading competitor in the neuromodulation market, offering spinal cord stimulation devices that compete directly with Nevro's Senza system for chronic pain management.

Abbott Laboratories

Abbott Laboratories competes in the chronic pain management space with its portfolio of neuromodulation products, including spinal cord stimulation devices that rival Nevro's offerings.

Boston Scientific

Boston Scientific is a key player in the neuromodulation sector, providing spinal cord stimulators that directly compete with Nevro's products for the treatment of chronic pain.

Smith & Nephew operates in the medical technology field, offering products that, while more focused on orthopedics, include treatments that can compete with Nevro's pain management solutions.

Zimmer Biomet Holdings, Inc. competes with Nevro through its diverse range of medical devices, some of which are used in pain management and can be seen as alternatives to spinal cord stimulation.

Stryker Corporation offers medical devices and equipment that, while broader in scope, include neuromodulation and pain management solutions that can compete with Nevro's offerings.

Globus Medical, Inc. focuses on musculoskeletal solutions, including devices for pain management that can compete with Nevro's spinal cord stimulation devices in certain applications.

Edwards Lifesciences

Edwards Lifesciences Corporation, primarily known for heart valves, also ventures into areas that can indirectly compete with Nevro's pain management solutions through their patient care innovations.

Integra Lifesciences

Integra LifeSciences Holdings Corporation offers products in neurosurgery and other medical device categories that, while not directly competing, offer alternative solutions to pain management, potentially competing with Nevro's market.

Analyst Ratings

8.43$Average Price Target

The highest estimate is $16.

From 12 ratings within the last 6 months. This is not an investment recommendation.

Buy

0%

Hold

75%

Sell

25%

About

Health Technology

Medical Specialties

Manufacturing

Surgical and Medical Instrument Manufacturing

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Show more...

CEO

D.Keith Grossman

Employees

1215

Country

US

ISIN

US64157F1030

Listings